Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T23:27:30.000Z thumbnail image
  5. Check
    32 days ago
    No Change Detected
  6. Check
    39 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T17:55:36.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T13:10:19.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.0 to v2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T05:14:03.000Z thumbnail image
  9. Check
    68 days ago
    Change Detected
    Summary
    The website has updated its contact information for several principal investigators and sub-investigators, with a new version revision from v2.13.3 to v2.14.0.
    Difference
    5%
    Check dated 2025-01-13T00:25:37.000Z thumbnail image
  10. Check
    97 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.1%
    Check dated 2024-12-15T01:36:29.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.